Author details

Full Name

Arnab Ghosh

Affiliation

ORCID

Career Start Year

2005

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
36526737	Correction to: Organ dysfunction, thrombotic events, and malignancies in patients with idiopathic multicentric Castleman disease: a population-level US health claims analysis.	Leukemia	2023
36103879	Proteomic and functional characterization of intra-tumor heterogeneity in human endometrial cancer.	Cell Reports Medicine	2022
36106631	Increased p53 expression induced by APR-246 reprograms tumor-associated macrophages to augment immune checkpoint blockade.	J Clin Invest	2022
36175555	Organ dysfunction, thrombotic events and malignancies in patients with idiopathic multicentric castleman disease: a population-level US health claims analysis.	Leukemia	2022
33504943	Correction: Generation and characterization of a novel hematopoietic progenitor cell line with DC differentiation potential.	Leukemia	2021
33745223	CCN5 activation by free or encapsulated EGCG is required to render triple-negative breast cancer cell viability and tumor progression.	Pharmacol Res Perspect	2021
33588426	CTLA-4 blockade drives loss of T stability in glycolysis-low tumours.	Nature	2021
34171309	Pharmacologic modulation of RNA splicing enhances anti-tumor immunity.	Cell	2021
33875794	Correction: Generation and characterization of a novel hematopoietic progenitor cell line with DC differentiation potential.	Leukemia	2021
32712326	Prognostic Factors for Postrelapse Survival after ex Vivo CD34-Selected (T Cell-Depleted) Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma.	Biology of Blood and Marrow Transplantation	2020
32402291	InÂ Vivo Cell Fate Tracing Provides No Evidence for Mesenchymal to Epithelial Transition in Adult Fallopian Tube and Uterus.	Cell Reports	2020
31883834	Endometrial Axin2 Cells Drive Epithelial Homeostasis, Regeneration, and Cancer following Oncogenic Transformation.		2020
31808941	Checkpoint inhibitors in AML: are we there yet?	British Journal of Haematology	2020
31479431	Chimeric antigen receptor-induced BCL11B suppression propagates NK-like cell development.	Journal of Clinical Investigation	2019
30499020	Protein PEGylation for cancer therapy: bench to bedside.	Journal of Cell Communication and Signaling	2019
30610526	Aspirin suppresses tumor cell-induced angiogenesis and their incongruity.	Journal of Cell Communication and Signaling	2019
31088416	Management and outcomes of proteasome inhibitor associated chalazia and blepharitis: a case series.	BMC Ophthalmology	2019
30915617	Microenvironment-sensing, nanocarrier-mediated delivery of combination chemotherapy for pancreatic cancer.	Journal of Cell Communication and Signaling	2019
30865368	Proteomic Analysis of Stromal and Epithelial Cell Communications in Human Endometrial Cancer Using a Unique 3D Co-Culture Model.	Proteomics	2019
31217893	Cyr61/CCN1 targets for chemosensitization in pancreatic cancer.	Oncotarget	2019
30787177	CYR61/CCN1 Regulates dCK and CTGF and Causes Gemcitabine-resistant Phenotype in Pancreatic Ductal Adenocarcinoma.	Mol Cancer Ther	2019
29813119	MIND model for triple-negative breast cancer in syngeneic mice for quick and sequential progression analysis of lung metastasis.	PLoS One	2018
29370782	Leptin-induced ER-Î±-positive breast cancer cell viability and migration is mediated by suppressing CCN5-signaling via activating JAK/AKT/STAT-pathway.	BMC Cancer	2018
29414775	The MAZ transcription factor is a downstream target of the oncoprotein Cyr61/CCN1 and promotes pancreatic cancer cell invasion via CRAF-ERK signaling.	Journal of Biological Chemistry	2018
29105517	CAR T cell therapy for multiple myeloma: where are we now and where are we headed?	Leukemia and Lymphoma	2018
28067900	Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity.	Nat Med	2017
28450698	Deficiency of CCN5/WISP-2-Driven Program in breast cancer Promotes Cancer Epithelial cells to mesenchymal stem cells and Breast Cancer growth.	Scientific Reports	2017
28530705	CCN5/WISP-2 restores ER-â¿ in normal and neoplastic breast cells and sensitizes triple negative breast cancer cells to tamoxifen.	Oncogenesis	2017
28743800	genetic cell lineage tracing reveals that oviductal secretory cells self-renew and give rise to ciliated cells.	Development (Cambridge)	2017
28872470	Stop and go: hematopoietic cell transplantation in the era of chimeric antigen receptor T cells and checkpoint inhibitors.	Current Opinion in Oncology	2017
27541366	Human pancreatic cancer progression: an anarchy among CCN-siblings.	Journal of Cell Communication and Signaling	2016
27240340	The miRacle in Pancreatic Cancer by miRNAs: Tiny Angels or Devils in Disease Progression.	International Journal of Molecular Sciences	2016
27138041	Generation of Genetically Engineered Precursor T-Cells From Human Umbilical Cord Blood Using an Optimized Alpharetroviral Vector Platform.	Mol Ther	2016
27473382	Exosomes in carcinogenesis: molecular palkis carry signals for the regulation of cancer progression and metastasis.	J Cell Commun Signal	2016
27828943	Overcoming resistance to checkpoint blockade therapy by targeting PI3KÎ³ in myeloid cells.	Nature	2016
24329800	Genetically engineered donor T cells to optimize graft-versus-tumor effects across MHC barriers.	Immunological Reviews	2014
23733752	PLZF confers effector functions to donor T cells that preserve graft-versus-tumor effects while attenuating GVHD.	Cancer Research	2013
23434824	Nrf2 regulates haematopoietic stem cell function.	Nature Cell Biology	2013
23676461	Adoptively transferred TRAIL+ T cells suppress GVHD and augment antitumor activity.	Journal of Clinical Investigation	2013
22113945	Hyaluronan synthase HAS2 promotes tumor progression in bone by stimulating the interaction of breast cancer stem-like cells with macrophages and stromal cells.	Cancer Research	2012
22547653	Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation.	Journal of Experimental Medicine	2012
22921121	Interleukin-22 protects intestinal stem cells from immune-mediated tissue damage and regulates sensitivity to graft versus host disease.	Immunity	2012
22383805	Interleukin-22 drives endogenous thymic regeneration in mice.	Science	2012
21978997	B- and T-lymphocyte attenuator targeting protects against the acute phase of graft versus host reaction by inhibiting donor anti-host cytotoxicity.	Transplantation	2011
19955659	The cytolytic molecules Fas ligand and TRAIL are required for murine thymic graft-versus-host disease.	Journal of Clinical Investigation	2010
20511541	Concurrent visualization of trafficking, expansion, and activation of T lymphocytes and T-cell precursors in vivo.	Blood	2010
20463307	Inhibition of neovascularization to simultaneously ameliorate graft-vs-host disease and decrease tumor growth.	Journal of the National Cancer Institute	2010
19737867	NOD2 regulates hematopoietic cell function during graft-versus-host disease.	Journal of Experimental Medicine	2009
19182207	Donor T cells primed on leukemia lysate-pulsed recipient APCs mediate strong graft-versus-leukemia effects across MHC barriers in full chimeras.	Blood	2009
18481382	Cytotoxic T cells reactive to an immunodominant leukemia-associated antigen can be specifically primed and expanded by combining a specific priming step with nonspecific large-scale expansion.	J Immunother	2008